Filing Details

Accession Number:
0002058093-25-000002
Form Type:
13G Filing
Publication Date:
2025-05-14 20:00:00
Filed By:
INFINITUM ASSET MANAGEMENT, LLC
Company:
Arrivent Biopharma Inc.
Filing Date:
2025-05-15
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
INFINITUM ASSET MANAGEMENT, LLC 0 2,066,238 6.1%
Infinitum Cayman Master, Ltd. 0 2,066,238 6.1%
Infinitum Partners GP, LLC 0 2,066,238 6.1%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox checked   Rule 13d-1(d)






SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G


 
INFINITUM ASSET MANAGEMENT, LLC
 
Signature:/s/ John Yetimoglu
Name/Title:Chief Investment Officer
Date:05/15/2025
 
Infinitum Cayman Master, Ltd.
 
Signature:/s/ John Yetimoglu
Name/Title:Chief Investment Officer
Date:05/15/2025
 
Infinitum Partners GP, LLC
 
Signature:/s/ John Yetimoglu
Name/Title:Chief Investment Officer
Date:05/15/2025